trending Market Intelligence /marketintelligence/en/news-insights/trending/vBJ06cKGJlYh3r6cXubE5g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Inspyr acquires Lewis & Clark Pharmaceuticals

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Inspyr acquires Lewis & Clark Pharmaceuticals

Inspyr Therapeutics Inc. on July 31 acquired privately held biotechnology company Lewis and Clark Pharmaceuticals Inc. in an all-stock transaction.

As consideration for the acquisition, the company agreed to issue an aggregate of 7,122,172 common shares to Lewis & Clark shareholders, resulting in the shareholders owning 50% of the issued and outstanding capital stock of Inspyr after the closing of the transaction.

In addition, Inspyr's board appointed John Montgomery, a principal of Lewis & Clark, to the board in connection with the deal. Montgomery's appointment, effective July 31, increases the size of the board to seven members from six members.